NCT04313634View on ClinicalTrials.gov

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

June 9, 2020

Primary Completion Date

June 6, 2023

Study Completion Date

June 6, 2023

Conditions
Healthy
Interventions
DRUG

Dasatinib

Dasatinib will be supplied as 100 mg tablet white to off-white, biconvex, oval, film- coated

DRUG

Quercetin

Quercetin will be supplied as quercetin phytosome (sophora japonica concentrate (leaf) / phosphatidylcholine complex from Sunflower) 250 mg

DRUG

Fisetin

Fisetin will be supplied in 100 mg capsules to be administered orally

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

All Listed Sponsors
lead

Sundeep Khosla, M.D.

OTHER

NCT04313634 - Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans | Biotech Hunter | Biotech Hunter